Facial Blemishes and Quality of Life

Cosmetic Dermatology

Volumn 17, Issue 2, 2004, Pages 107-113

  McMichael, Amy J ^a   Shew, Katherine ^b   Cayce, Kimberly A ^b   Balkrishnan, Rajesh ^d   Feldman, Steven R ^c   Rapp, Stephen R ^c  

^a Department of Dermatology ^*

^b Dermatology

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOMA; CAREER; CHLOASMA; FACE DISORDER; FACIAL BLEMISH; HEALTH; HUMAN; NEVUS FLAMMEUS; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SCAR; SELF CONCEPT; SOCIAL ISOLATION; VITILIGO;

EID: 1242352625     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Roberts NC. Corrective cosmetics-need, evaluation and use. Cutis. 1988;41:439-441.
2. Jemec GBE, Wulf HC. Patient-physician consensus on quality of life in dermatology. Clin Exp Dermatol. 1996;21:177-179.
3. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37:41-50.
4. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000;39:801-806.
5. Lanigan SW, Cotterill JA. Psychological disabilities amongst patients with port wine stains. Br J Dermatol. 1989;121:209-215.
6. Kalick SM, Goldwyn RM, Noe JM. Social Issues and body image concerns of port wine stain patients undergoing laser therapy. Lasers Surg Med. 1981;1:205-213.
7. Wojnarowska F. The disfigured patient. Practitioner. 1988;232:1022-1025.
8. Lanigan S. The stigma of port-wine stains. Br J Hosp Med. 1991;45:274-276.
9. Dixon JA, Rotering RH, Huether SE. Patient's evaluation of argon laser therapy of port wine stain, decorative tattoo, and essential telangiectasia. Lasers Surg Med. 1984;4:181-190.
10. Piliavin IM, Piliavin JA, Rodin J. Costs, diffusion, and the stigmatized victim. J Pers Soc Psychol. 1975;32:429-438.
11. Finlay AY, Ryan TJ. Disability and handicap in dermatology. Int J Dermatol. 1996;35:305-311.
12. Porter JR, Beuf AH, Lerner A, et al. Psychosocial effect of vitiligo: a comparison of vitiligo patients with "normal" control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol. 1986;15:220-224.
13. Porter J, Beuf A, Nordlund JJ, et al. Personal responses of patients to vitiligo: the importance of the patient-physician interaction. Arch Dermatol. 1978;114:1384-1385.
14. Porter J, Beuf AH, Lerner A, et al. Response to cosmetic disfigurement: patients with vitiligo. Cutis. 1987;39:493-494.
15. Porter JR, Beuf AH, Lerner AB, et al. The effect of vitiligo on sexual relationships. J Am Acad Dermatol. 1990;22:221-222.
16. Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol. 1996;35:895-898.
17. Porter JR, Beuf AH. Racial variation in reaction to physical stigma: a study of degree of disturbance by vitiligo among black and white patients. J Health Soc Behav. 1991;32:192-204.
18. Balkrishnan R, Housman TS, Allen BR, et al. Predictors of health-related quality of life in women with melasma. Cosmet Dermatol. April 2003;16:25-26, 29-30.
19. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136:305-314.
20. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-577.
21. Hanna S, Sharma J, Klotz J. Acne vulgaris: more than skin deep. Dermatol Online J. 2003;9:8.
22. Baldwin HE. The interaction between acne vulgarls and the psyche. Cutis. 2002;70:133-139.
23. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140:672-676.
24. Niemeier V, Kupfer J, Demmelbauer-Ebner M, et al. Coping with acne vulgads: evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology. 1998;196:108-115.
25. Rapp SR, Feldman SR, Exum ML, et al. Psodasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407.
26. Leary MR, Rapp SR, Herbst KC, et al. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol, 1998;17:530-536.
27. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(suppl):57-61.
28. Weiss SC, Bergstrom KG, Weiss SA, et al. Quality of life considerations in psoriasis treatment. Dermatol Nurs. 2003;15:120-127.
29. de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(suppl 58):33-36.
30. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
31. Aziah MS, Rosnah T, Mardziah A, et al. Childhood atopic dermatitis: a measurement of quality of life and family impact. Med J Malaysia. 2002;57:329-339.
32. Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41:323-332.
33. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41:151-158.
34. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health RI. 2001;84:294-295.
35. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610-616.
36. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med. 1985;20:425-429.
37. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. J Dermatol. 2001;28:419-423.
38. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53-63.
39. Wessely SC, Lewis GH. The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry. 1989;155:686-691.
40. Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol. 1995;34:101-115.
41. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236-244.
42. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988;118:195-201.
43. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg. 1998;17:291-296.
44. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
45. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989;14:194-198.
46. Hahn HB, Melfi CA, Chuang TY, et al. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol. 2001;45:44-48.
47. Harlow D, Poyner T, Finlay AY, et al. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol. 2000;143:979-982.